Journal
LANCET NEUROLOGY
Volume 8, Issue 5, Pages 475-490Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(09)70063-8
Keywords
-
Categories
Funding
- National Institutes of Health [K08NS058800-02]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS058800] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Acquired myasthenia gravis (MG) is an autoirrimune disorder of the neuromuscular junction in which patients experience fluctuating skeletal muscle weakness that often affects selected muscle groups preferentially. The target of the autoimmune attack in most cases is the skeletal muscle acetylcholine receptor (AChR), but in others, non-AChR components of the neuromuscular junction, such as the muscle-specific receptor tyrosine kinase, are targeted. The pathophysiological result is muscle endplate dysfunction and consequent fatigable muscle weakness. Clinical presentations vary substantially, both for anti-AChR positive and negative MG, and accurate diagnosis and selection of effective treatment depends on recognition of less typical as well as classic disease phenotypes. Accumulating evidence suggests that clinical MG subgroups might respond differently to treatment. In this Review, we provide current information about the epidemiology, immunopathogenesis, clinical presentations, diagnosis, and treatment of MG, including emerging therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available